This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hyperion Therapeutics Announces Three New Additions To Its Senior Leadership Team

SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company has added three new executives to its leadership team: senior vice president, governmental affairs and chief legal officer, Ashley Gould, senior vice president, Corporate and Business Development, Natalie Holles and vice president, Investor Relations and Corporate Communications, Sylvia Wheeler.

"I am pleased with the varied breadth of related industry expertise each of these individuals brings to our business," said Donald J. Santel, Chief Executive Officer of Hyperion. "As we continue to mature as a company, their respective experience and skills will be instrumental in helping to guide our growth as a commercial enterprise seeking to deliver life-changing treatments to the patient and medical communities we serve."

Senior Vice President, Governmental Affairs and Chief Legal Officer; Ashley Gould

Ms. Gould will be responsible for serving as the company's in-house legal counsel and leading public and governmental affairs activities. Ms. Gould recently served as vice president, Corporate Development and chief legal officer at 23andMe, a personal genetics company. Prior to joining 23andMe in 2007, Ms Gould was vice president, Legal Affairs at CoTherix, Inc., a biopharmaceutical company. Previously, Ms. Gould was associated with the law firms of Wilson Sonsini Goodrich & Rosati PC and O'Melveny & Myers LLP. Ms. Gould received her JD from the University of San Francisco School of Law and her B.S. in Political Economy of Natural Resources from the University of California, Berkeley.

Senior Vice President, Corporate and Business Development; Natalie Holles

Ms. Holles will lead Hyperion's efforts to bring in new products to complement the existing portfolio and identify other ways to grow the company through external industry relationships. For the past five years, Ms. Holles has worked as an executive-level consultant leading business development activities for several life sciences companies. Most recently she served as executive vice president of Corporate Development for Immune Design, a leading cancer immunotherapy company based in Seattle. Ms. Holles also brings extensive in-house business development experience from KAI Pharmaceuticals, and InterMune, Inc. Ms. Holles began her career in the industry as a Marketing Planning Associate at Genentech, Inc. Ms. Holles received her M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado and her A.B. in Human Biology from Stanford University.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs